BNP Paribas Financial Markets
TAK icon

BNP Paribas Financial Markets’s Takeda Pharmaceutical TAK Stock Holding History

BNP Paribas Financial Markets’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.53M Buy
190,413
+4,864
+3% +$85.4K ﹤0.01% 2287
2025
Q4 		$2.89M Buy
185,549
+174,355
+1,558% +$2.49M ﹤0.01% 2396
2025
Q3 		$164K Sell
11,194
-651
-5% -$9.67K ﹤0.01% 4099
2025
Q2 		$183K Buy
11,845
+11,169
+1,652% +$165K ﹤0.01% 3797
2025
Q1 		$10.1K Sell
676
-500,001
-100% -$7.01M ﹤0.01% 4714
2024
Q4 		$6.63M Buy
500,677
+497,457
+15,449% +$6.83M ﹤0.01% 1603
2024
Q3 		$45.8K Buy
3,220
+2,596
+416% +$36.8K ﹤0.01% 3630
2024
Q2 		$8.07K Sell
624
-88
-12% -$1.17K ﹤0.01% 3742
2024
Q1 		$9.89K Hold
712
– – ﹤0.01% 3689
2023
Q4 		$10.2K Sell
712
-83
-10% -$1.18K ﹤0.01% 3713
2023
Q3 		$12.3K Sell
795
-1,986
-71% -$30.7K ﹤0.01% 3607
2023
Q2 		$43.7K Buy
2,781
+759
+38% +$12.4K ﹤0.01% 3505
2023
Q1 		$33.3K Buy
2,022
+1,062
+111% +$16.9K ﹤0.01% 3477
2022
Q4 		$15K Hold
960
– – ﹤0.01% 3575
2022
Q3 		$12.5K Sell
960
-2,804
-74% -$39K ﹤0.01% 4157
2022
Q2 		$52.8K Sell
3,764
-90,613
-96% -$1.29M ﹤0.01% 3545
2022
Q1 		$1.35M Sell
94,377
-178,625
-65% -$2.62M ﹤0.01% 2110
2021
Q4 		$3.72M Buy
273,002
+229,978
+535% +$3.23M 0.01% 1552
2021
Q3 		$705K Buy
43,024
+888
+2% +$14.9K ﹤0.01% 2580
2021
Q2 		$709K Sell
42,136
-215,754
-84% -$3.67M ﹤0.01% 2367
2021
Q1 		$4.71M Sell
257,890
-75,000
-23% -$1.35M 0.01% 1205
2020
Q4 		$6.06M Buy
332,890
+21,678
+7% +$380K 0.01% 1029
2020
Q3 		$5.55M Sell
311,212
-30,183
-9% -$550K 0.01% 1032
2020
Q2 		$6.12M Buy
341,395
+8,539
+3% +$153K 0.01% 956
2020
Q1 		$5.05M Buy
332,856
+13,837
+4% +$251K 0.01% 976
2019
Q4 		$6.29M Buy
319,019
+5,064
+2% +$96.9K 0.01% 1080
2019
Q3 		$5.4M Sell
313,955
-6,730
-2% -$116K 0.01% 1037
2019
Q2 		$5.68M Buy
+320,685
New +$5.84M 0.01% 982

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets's TAK Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Takeda Pharmaceutical (TAK) stake by 2.6% in Q1 2026, buying an estimated $85.4K and bringing the position to 190,413 shares worth $3.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2287.

BNP Paribas Financial Markets first reported a position in TAK in Q2 2019 and has held it in 28 quarters since. The position peaked at $6.63M in Q4 2024. 359 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • BNP Paribas Financial Markets held 190,413 shares of Takeda Pharmaceutical worth $3.53M as of Q1 2026.
  • BNP Paribas Financial Markets bought 4,864 Takeda Pharmaceutical shares in Q1 2026, an estimated $85.4K.
  • Takeda Pharmaceutical made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #2287 holding.
  • BNP Paribas Financial Markets first reported a position in Takeda Pharmaceutical in Q2 2019 and has held it in 28 quarters since.
  • BNP Paribas Financial Markets's Takeda Pharmaceutical position peaked at $6.63M in Q4 2024.
  • 359 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.